Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

FOLFIRINOX 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-05-2018 | Pancreatic cancer | News | Article

    Pancreatic R0 resection rate high with FOLFIRINOX plus chemoradiotherapy

    Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy results in a high margin-negative resection rate in patients with borderline resectable pancreatic cancer, phase II trial data show.

    Published in:
    JAMA Oncol 2018; Advance online publication
  2. 13-06-2018 | Pancreatic cancer | ASCO 2018 | Article

    Adjuvant mFOLFIRINOX ‘new standard of care’ for pancreatic cancer

    Adjuvant treatment with a modified FOLFIRINOX regimen significantly improves survival relative to gemcitabine in patients with resected pancreatic ductal adenocarcinoma, according to findings presented at the ASCO Annual Meeting 2018, held in Chicago, Illinois, USA.

    Published in:
    ASCO Annual Meeting 2018; Chicago, Illinois, USA
  3. play
    08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

    Researcher comment: Adjuvant mFOLFIRINOX shows benefits over gemcitabine in pancreatic cancer

    Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58). Read the related news story Watch the accompanying expert commentary

  4. 22-05-2017 | Pancreatic cancer | News | Article

    Targeting mitochondrial metabolism shows promise in pancreatic cancer

    Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.

    Published in:
    Lancet Oncol 2017; Advance online publication
  5. 11-06-2018 | Pancreatic cancer | ASCO 2018 | Article

    Improved outcomes with preoperative CRT in pancreatic cancer

    The next step, after the final analysis of the trial, would be “to find even more effective preoperative treatments,” such as FOLFIRINOX alone or with stereotactic body radiation therapy, the presenter noted in a press release.

    Published in:
    ASCO Annual Meeting 2018; Chicago, Illinois, USA
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.